Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is now up 71.67% compared to a 12-month low of $1.20. We have seen the price to move -6.79% lower and get settled at $2.06 on 11/20/2017. At recent session, it appeared stuck in a range of $1.8 to $2.15. This company shares are 230.1% off its target price of $6.8 and the current market capitalization stands at $28.9M. The recent change has given its price a 26.18% lead over SMA 50 and -89.82% deficit over its 52-week high. The stock witnessed 24.1% gains, 57.25% gains and 21.89% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANTH’s volatility during a week at 17.65% and during a month it has been found around 13.39%.Anthera Pharmaceuticals, Inc. (ANTH) Top Holders
Institutional investors currently hold around $5 million or 18.1% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $2.22 million in Anthera Pharmaceuticals, Inc., which represents roughly 7.7% of the company’s market cap and approximately 44.48% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 359,751 shares of the stock are valued at $795 thousand. The third largest holder is Millennium Management Llc, which currently holds $265 thousand worth of this stock and that ownership represents nearly 0.92% of its market capitalization.Anthera Pharmaceuticals, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 17 institutional holders increased their position in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by some 200,243 shares, 21 decreased positions by 931,143 and 10 held positions by 1,117,380. That puts total institutional holdings at 2,248,766 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 91,915 shares while 12 institutional investors sold out their entire positions totaling 243,255 shares.Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Insider Trades
Multiple company employees have indulged in significant insider trading. Anthera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Thompson John Craig has acquired 8,550 shares of Anthera Pharmaceuticals, Inc. (ANTH) in trading session dated Sep. 20, 2017. These shares are worth $11,286 and were traded at $1.32 each. The SEC filing shows that Thompson John Craig performed a purchase of 10,400 shares. The President & CEO added these shares by way of transaction on Sep. 07, 2017. The company’s shares were assimilated at $1.43 per share worth to an investment of some $14,872 on account of Thompson John Craig.
Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. (ANTH) in the open market. In a transaction dated Sep. 07, 2017, the shares were bought at an average price of $1.34, giving away a sum of $6,700. After this purchase, 16,793 common shares of ANTH are directly owned by the insider, with total stake valued at $34,594.
In the transaction dated Nov. 13, 2015, the great number of shares disposed came courtesy the Chief Medical Officer; Hislop Colin disposed a total of 1,563 shares at an average price of $42.48, amounting to approximately $66,396. The insider now directly owns 2,631 shares worth $5,420.Anthera Pharmaceuticals, Inc. (ANTH) Analyst Guide
Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.